CoChat

Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy

Open access
Bessa, Cláudia, Soares, Joana, Raimundo, Liliana, Loureiro, Joana B., Gomes, Célia, Reis, Flávio, Soares, Miguel L., Santos, Daniel, Dureja, Chetna, Chaudhuri, Saumya R., Lopez-Haber, Cynthia, Kazanietz, Marcelo G., Gonçalves, Jorge, Simões, Maria F., Rijo, Patrícia, Saraiva, Lucília · 2018 · Cell Death & Disease
Cited by 123

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Protein kinase C (PKC) isozymes play major roles in human diseases, including cancer. Yet, the poor understanding of isozymes-specific functions and the limited availability of selective pharmacological modulators of PKC isozymes have limited the clinical translation of PKC-targeting agents. Here, we report the first small-molecule PKCδ-selective activator, the 7 α-acetoxy-6 β-benzoyloxy-12-O-benzoylroyleanone (Roy-Bz), which binds to the PKCδ-C1-domain. Roy-Bz potently inhibited the proliferation of colon cancer cells by inducing a PKCδ-dependent mitochondrial apoptotic pathway involving caspase-3 activation. In HCT116 colon cancer cells, Roy-Bz specifically triggered the translocation of PKCδ but not other phorbol ester responsive PKCs. Roy-Bz caused a marked inhibition in migration of HCT116 cells in a PKCδ-dependent manner. Additionally, the impairment of colonosphere growth and formation, associated with depletion of stemness markers, indicate that Roy-Bz also targets drug-resistant cancer stem cells, preventing tumor dissemination and recurrence. Notably, in xenograft mouse models, Roy-Bz showed a PKCδ-dependent antitumor effect, through anti-proliferative, pro-apoptotic, and anti-angiogenic activities. Besides, Roy-Bz was non-genotoxic, and in vivo it had no apparent toxic side effects. Collectively, our findings reveal a novel promising anticancer drug candidate. Most importantly, Roy-Bz opens the way to a new era on PKC biology and pharmacology, contributing to the potential redefinition of the structural requirements of isozyme-selective agents, and to the re-establishment of PKC isozymes as feasible therapeutic targets in human diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-017-0154-9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 123

Metadata

Authors
Bessa, C., Soares, J., Raimundo, L., Loureiro, J. B., Gomes, C., Reis, F., Soares, M. L., Santos, D., Dureja, C., Chaudhuri, S. R., Lopez-Haber, C., Kazanietz, M. G., Gonçalves, J., Simões, M. F., Rijo, P., & Saraiva, L.
Venue
Cell Death & Disease
Published
2018-01-18
Volume
9
Issue
2
Pages
23-23
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2785141812
Cited by
123
References
1
FWCI
8.32
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy. https://app.cochat.ai/papers/10.1038/s41419-017-0154-9
The paper
Bessa, C., Soares, J., Raimundo, L., Loureiro, J. B., Gomes, C., Reis, F., Soares, M. L., Santos, D., Dureja, C., Chaudhuri, S. R., Lopez-Haber, C., Kazanietz, M. G., Gonçalves, J., Simões, M. F., Rijo, P., & Saraiva, L. (2018). Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy. Cell Death & Disease. https://doi.org/10.1038/s41419-017-0154-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.